The patent cliff approaching between 2025 and 2030 is the defining strategic challenge facing the pharmaceutical industry. An estimated $300 billion in branded drug revenues will face loss of exclusivity during this period — including Keytruda, Dupixent, Skyrizi, Eliquis, Ozempic, Imbruvica, and dozens of other major products. AbbVie navigated the steepest single-product patent cliff in history through a multi-year transition strategy built around Skyrizi and Rinvoq that was executed with near-flawless commercial discipline. Merck faces the industry’s most consequential upcoming patent cliff in Keytruda, which represents approximately 49% of pharmaceutical sales.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Patent Cliff Analysis 2025-2030
• Lifecycle Extension Strategies
• Biosimilar Entry Dynamics
• Successor Product Strategy
• M&A as Patent Cliff Defense
• AbbVie Humira Case Study
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Patent Cliff Analysis 2025-2030
4. Lifecycle Extension Strategies
5. Biosimilar Entry Dynamics
6. Successor Product Strategy
7. M&A as Patent Cliff Defense
8. AbbVie Humira Case Study
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Sandoz
Celltrion
Samsung Bioepis
Coherus
Organon
Amneal
Viatris
Fresenius Kabi
